Open AccessMechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells
Author(s) -
Wang Cong,
Lin Shaoqiang,
Nie Yanfang,
Jia Xinglong,
Wang Jing,
Xiao Jian,
Wu Jianzhang,
Li Xiaokun,
Wu Xiaoping
Publication year - 2010
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01501.x
Subject(s) - basic fibroblast growth factor , colorectal cancer , cancer cell , cancer , cell cycle , cell growth , cancer research , peptide , cell culture , medicine , cell , endocrinology , biology , growth factor , receptor , biochemistry , genetics
Colon cancer is a leading cause of morbidity and mortality in Western countries. Basic fibroblast growth factor (bFGF) was up‐regulated in patients with colon cancer and was considered as a potential therapeutic target. In this study, we first demonstrated that a novel bFGF‐binding peptide (named P7) inhibited proliferation of several colon cancer cell lines including HT‐29, LoVo, and Caco2 cells stimulated by bFGF. Further investigations with HT‐29 cells indicated that P7 arrested the cell cycle at the G0/G1 phase of bFGF‐stimulated cells, reduced the levels of phospho‐Erk1/Erk2 induced by bFGF, and caused significant changes in the expression of proteins related to proliferation, cell cycle, and cancer. Our results suggested that the bFGF‐binding peptide has a potential antitumor effect on colon cancer. ( Cancer Sci 2010; 101: 1212–1218)